MES 1007
Alternative Names: C3 - Mesentech; MES-1007Latest Information Update: 28 Dec 2024
At a glance
- Originator Simon Fraser University
- Developer Mesentech
- Class Benzamides; Carboxylic acids; Drug conjugates; Fluorinated hydrocarbons; Phosphorus compounds; Prostaglandins; Pyrrolidinones; Small molecules
- Mechanism of Action Prostaglandin E EP4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone disorders; Osteogenesis imperfecta
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Bone-disorders in Canada (Intraperitoneal, Injection)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Osteogenesis-imperfecta in Canada (Intraperitoneal, Injection)
- 10 Nov 2020 Mesentech plans a clinical trial for Bone disorders in